Submitted by Jeffrey Lake on Tue, 02/07/2017 - 4:22pm Which of the following is your specialty? * Medical oncologist/hematologist Radiological oncologist Oncology nurse/oncology nurse practitioner Other... please specify Which of the following is your specialty? Other... please specify Please indicate the types of cancer you see/treat most often: * Breast Cancer Colorectal Cancer Ovarian Lung Other...please specify Please indicate the types of cancer you see/treat most often: Other...please specify Please complete the following sentence based on your clinical experience: * Despite the availability of a range of antiemetic agents for the management of chemotherapy induced nausea and vomiting (CINV), % of patients are still not completely protected against this common side effect. Please rate your familiarity with the 2016 MASCC/ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting in advanced cancer patients * Not at all familiar Somewhat familiar Very familiar Extremely familiar Of your patients receiving a chemotherapy regimen with a low emetogenic potential, what percentage are also receiving one or more antiemetic agents to manage CINV? * None Less than 25% 26% - 50% 51% - 75% More than 75% Don’t know Of your patients receiving a moderately emetogenic chemotherapy regimen, what percentage are also receiving one or more antiemetic agents to manage CINV? * None Less than 25% 26% - 50% 51% - 75% More than 75% Don’t know Of your patients receiving a highly emetogenic chemotherapy regimen, what percentage are also receiving one or more antiemetic agents to manage CINV? * None Less than 25% 26% - 50% 51% - 75% More than 75% Don’t know How confident are you in your ability to predict which patients are most at risk of experiencing CINV, including those who may experience acute and/or delayed CINV? * Not at all confident Somewhat confident Very confident Extremely confident How confident are you in your ability to select the right combination of antiemetic therapies to prevent both acute and delayed CINV? * Not at all confident Somewhat confident Very confident Extremely confident Which of the following is an FDA-approved, antiemetic for the prevention of acute and delayed CINV due to highly emetogenic chemotherapy regimens? * Fosaprepitant Netupitant/Palonosetron combination Both Fosaprepitant and Netupitant/Palonosetron combination Dronabinol None of the above I don't know Which of the following agents is a 5HT3 receptor antagonist? * Rolapitant Olanzapine Palonosetron Prochlorperazine None of the Above Which of the following agents is an NK-1 receptor antagonist? * Rolapitant Olanzapine Palonosetron Prochlorperazine None of the Above Please rate your familiarity with the safety and efficacy of oral rolapitant for the prevention of delayed CINV. * Not at all familiar Somewhat familiar Very familiar Extremely familiar Please rate your familiarity with the safety and efficacy of IV and oral fosaprepitant for the prevention of acute and delayed CINV. * Not at all familiar Somewhat familiar Very familiar Extremely familiar Please rate your familiarity with the safety and efficacy of the oral combination netupitant/palonosetron in the prevention of acute and delayed CINV. * Not at all familiar Somewhat familiar Very familiar Extremely familiar If you are interested in participating in the raffle for a $100/€100 Amazon gift card, please fill out the following: First Name: Last Name: Email: Leave this field blank
